Showing 1 - 20 results of 35 for search 'Omarion~', query time: 4.46s Refine Results
  1. 1

    Integrated genomic analyses of ovarian carcinoma by Meyerson, Matthew L., Lander, Eric Steven

    Published 2012
    “…A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. …”
    Get full text
    Article
  2. 2
  3. 3

    UNRAVELING THE ORIGIN OF OVERIONIZED PLASMA IN THE GALACTIC SUPERNOVA REMNANT W49B by Lopez, Laura A., Pearson, Sarah, Ramirez-Ruiz, Enrico, Castro, Daniel, Yamaguchi, Hiroya, Slane, Patrick O., Smith, Randall K.

    Published 2015
    “…Using these results, we find that W49B is overionized in the west, with a gradient of overionization increasing from east to west. …”
    Get full text
    Get full text
    Article
  4. 4

    Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models by Na, Young Jeong, Fulci, Giulia, del Carmen, Marcela G., Birrer, Michael J., Ye, Hongye, Tanenbaum, Laura Melanie, Mantzavinou, Aikaterini, Cima, Michael J.

    Published 2017
    “…Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. …”
    Get full text
    Get full text
    Get full text
    Article
  5. 5

    Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Target ID4 by Ren, Yin, von Maltzhan, Geoffrey, Agrawal, Amit, Mesirov, Jill P., Lo, Justin H., Cheung, Hiu Wing, Cowley, Glenn S., Weir, Barbara A., Boehm, Jesse S., Tamayo, Pablo, Karst, Alison M., Liu, Joyce F., Hirsch, Michelle S., Drapkin, Ronny, Root, David E., Fogal, Valentina, Ruoslahti, Erkki, Hahn, William C., Bhatia, Sangeeta N

    Published 2014
    “…We used TPN in vivo to evaluate inhibitor of DNA binding 4 (ID4) as a novel oncogene. Treatment of ovarian tumor–bearing mice with ID4-specific TPN suppressed growth of established tumors and significantly improved survival. …”
    Get full text
    Get full text
    Get full text
    Article
  6. 6

    The Ligand Binding Domain of GCNF Is Not Required for Repression of Pluripotency Genes in Mouse Fetal Ovarian Germ Cells by Okumura, Leah M., Lesch, Bluma J., Page, David C.

    Published 2013
    “…Here we demonstrate that Gcnf is expressed in fetal ovarian germ cells, peaking at E14.5, when Oct4 and Nanog are silenced. …”
    Get full text
    Get full text
    Article
  7. 7
  8. 8
  9. 9

    Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules by Demirci, Utkan, Hasan, Tayyaba, Rizvi, Imran, Gurkan, Umut Atakan, Tasoglu, Savas, Alagic, Nermina, Celli, Jonathan P., Mensah, Lawrence B., Mai, Zhiming

    Published 2013
    “…Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage disease that is extensively disseminated intraperitoneally and prognosticates the poorest outcomes. …”
    Get full text
    Article
  10. 10

    A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy by Awuah, Samuel, Zheng, Yaorong, Bruno, Peter Michael, Hemann, Michael, Lippard, Stephen J.

    Published 2017
    “…Compound 2 effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the auto-crine-signaling loop IDO-AHR-IL6, which blocks kynurenine production and promotes T-cell proliferation. …”
    Get full text
    Get full text
    Get full text
    Get full text
    Article
  11. 11

    A 3D model of ovarian cancer cell lines on peptide nanofiber scaffold to explore the cell–scaffold interaction and chemotherapeutic resistance of anticancer drugs by Yang, Zehong, Zhao, Xiaojun

    Published 2014
    “…The cancer cell–nanofiber scaffold construct was cultured for 5 days, and the ovarian cancer cells had actively proliferative potential. …”
    Get full text
    Article
  12. 12

    Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival bearing tumors derived from Brca1-deficient ovarian cancer cells by Goldberg, Michael Solomon, Xing, Deyin, Ren, Yin, Orsulic, Sandra, Sharp, Phillip A., Bhatia, Sangeeta N

    Published 2011
    “…Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP1) with small molecules has been shown to be an effective treatment for ovarian cancer with BRCA mutations. Here, we report the in vivo administration of siRNA to Parp1 in mouse models of ovarian cancer. …”
    Get full text
    Get full text
    Get full text
    Article
  13. 13
  14. 14

    Naval Engineering A National Naval Obligation by Chryssostomidis, Chryssostomos, Bernitsas, Michael, Burke, David

    Published 2002
    Subjects: “…Naval Architecture and Marine Engineering…”
    Get full text
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20